| Literature DB >> 32154412 |
Aliyu Wappah Mahmud1, Gideon Adamu Shallangwa2, Adamu Uzairu2.
Abstract
Quantitative structure-activity relationships (QSAR) provides a model that link biological activities of compounds to thier chemical stuctures and molecular docking study reveals the interaction between drug and its target enzyme. These studies were conducted on 1,3-dioxoisoindoline-4-aminoquinolines with the aim of producing a model that could be used to design highly potent antiplasmodium. The compounds were first optimized using Density Functional Theory (DFT) with basis set B3LYP/6-31G∗ then their descriptors calculated. Genetic Function Algorithm (GFA) was used to select descriptors and build the model. One of the four models generated was found to be the best having internal and external squared correlation coefficient (R 2) of 0.9459 and 0.7015 respectively, adjusted squared correlation coefficient (R adj) of 0.9278, leave-one-out (LOO) cross-validation coefficient (Q 2 cv) of 0.8882. The model shows that antiplasmodial activities of 1,3-dioxoisoindoline-4-aminoquinolines depend on ATSC5i, GATS8p, minHBint3, minHBint5, MLFER_A and topoShape descriptors. The model was validated to be predictive, robust and reliable. Hence, it can predict the antiplasmodium activities of new 1,3-dioxoisoindoline-4-aminoquinolines.The docking result indicates strong binding between 1,3-dioxoisoindoline-4-aminoquinolines and Plasmodium falciparum lactate dehydrogenase (pfLDH), and revealed the important of the morpholinyl substituent and amide linker in inhibiting pfLDH. These results could serve as a model for designing novel 1,3-dioxoisoindoline-4-aminoquinolines as inhibitors of PfLDH with higher antiplasmodial activities.Entities:
Keywords: Antiplasmodium; Hybrid compounds; Molecular docking; Pharmaceutical chemistry; Physical chemistry; Plasmodium falciparum lactate dehydrogenase; QSAR; Theoretical chemistry
Year: 2020 PMID: 32154412 PMCID: PMC7056653 DOI: 10.1016/j.heliyon.2020.e03449
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 11,3-dioxoisoindoline-4-aminoquinolines.
Compounds of Figure 1 with their antiplasmodial activities.
| Compounds | R | m | N | IC50(nM) |
|---|---|---|---|---|
| 1 | H | 1 | 2 | 5.65 |
| 2 | H | 1 | 4 | 3.66 |
| 3 | H | 1 | 6 | 3.35 |
| 4 | H | 1 | 8 | 0.24 |
| 5 | H | 2 | 2 | 0.30 |
| 6 | H | 2 | 4 | 0.41 |
| 7 | H | 2 | 6 | 0.29 |
| 8 | H | 2 | 8 | 0.15 |
| 9 | H | 3 | 2 | 0.28 |
| 10 | H | 3 | 4 | 0.84 |
| 11 | H | 3 | 6 | 1.57 |
| 12 | H | 3 | 8 | 0.58 |
| 13 | F | 1 | 2 | 1.99 |
| 14 | F | 1 | 4 | 1.05 |
| 15 | F | 1 | 6 | 1.49 |
| 16 | F | 2 | 2 | 0.36 |
| 17 | F | 2 | 4 | 0.22 |
| 18 | F | 2 | 6 | 0.66 |
| 19 | Morpholinyl | 1 | 2 | 3.21 |
| 20 | Morpholinyl | 1 | 4 | 1.28 |
| 21 | Morpholinyl | 1 | 6 | 1.78 |
| 22 | Morpholinyl | 2 | 2 | 0.13 |
| 23 | Morpholinyl | 2 | 4 | 0.22 |
| 24 | Morpholinyl | 2 | 6 | 0.64 |
| 25 | Diethylamino | 1 | 2 | 1.14 |
| 26 | Diethylamino | 1 | 4 | 1.17 |
| 27 | diethylamino | 1 | 6 | 1.22 |
| 28 | diethylamino | 2 | 2 | 0.097 |
| 29 | diethylamino | 2 | 4 | 0.26 |
| 30 | diethylamino | 2 | 6 | 0.53 |
| 31 | 2-(piperazin-1-yl)ethan-1-ol | 1 | 2 | 1.04 |
| 32 | 2-(piperazin-1-yl)ethan-1-ol | 1 | 4 | 0.86 |
| 33 | 2-(piperazin-1-yl)ethan-1-ol | 1 | 6 | 0.46 |
| 34 | 2-(piperazin-1-yl)ethan-1-ol | 2 | 2 | 0.28 |
| 35 | 2-(piperazin-1-yl)ethan-1-ol | 2 | 4 | 0.14 |
| 36 | 2-(piperazin-1-yl)ethan-1-ol | 2 | 6 | 0.18 |
Validation parameters for the selected model.
| S/N | Parameter | Value |
|---|---|---|
| 1 | Friedman LOF | 0.083 |
| 2 | R2train | 0.946 |
| 3 | Adjusted | 0.928 |
| 4 | Cross-validated | 0.888 |
| 5 | Significant regression | Yes |
| 6 | Significance-of-regression F-value | 48.26 |
| 7 | Critical SOR F-value (95%) | 2.672 |
| 8 | Replicate points | 0 |
| 9 | Computed experimental error | 0 |
| 10 | Lack-of-fit points | 18 |
| 11 | Min expt. error for nonsignificant LOF (95%) | 0.103 |
| 12 | R2test | 0.702 |
Experimental and predicted pIC50 of 1,3-dioxoisoindoline-4-aminoquinolines with their residuals.
| Compounds | Experimental pIC50 | Predicted pIC50 | Residual |
|---|---|---|---|
| 1 | 5.248 | 5.331 | -0.083 |
| 2 | 5.437 | 5.523 | -0.087 |
| 3 | 5.475 | 5.523 | -0.048 |
| 4 | 6.62 | 6.355 | 0.2644 |
| 5 | 6.523 | 6.716 | -0.193 |
| 6 | 6.387 | 6.777 | -0.39 |
| 7 | 6.538 | 6.434 | 0.1035 |
| 8 | 6.824 | 6.914 | -0.09 |
| 9 | 6.553 | 6.518 | 0.0352 |
| 10 | 6.076 | 5.909 | 0.1669 |
| 11 | 5.804 | 5.746 | 0.0581 |
| 12 | 6.237 | 6.236 | 0.0007 |
| 13 | 5.701 | 5.655 | 0.0459 |
| 14 | 5.979 | 5.8 | 0.179 |
| 15 | 5.827 | 6.006 | -0.179 |
| 16 | 6.444 | 6.447 | -0.003 |
| 17 | 6.658 | 6.526 | 0.1317 |
| 18 | 6.18 | 6.204 | -0.024 |
| 19 | 5.493 | 5.57 | -0.077 |
| 20 | 5.893 | 5.53 | 0.363 |
| 21 | 5.75 | 5.796 | -0.046 |
| 22 | 6.886 | 6.793 | 0.0932 |
| 23 | 6.658 | 6.634 | 0.0238 |
| 24 | 6.194 | 6.342 | -0.148 |
| 25 | 5.943 | 5.998 | -0.055 |
| 26 | 5.932 | 5.912 | 0.0194 |
| 27 | 5.914 | 6.147 | -0.233 |
| 28 | 7.013 | 6.726 | 0.287 |
| 29 | 6.585 | 6.566 | 0.0193 |
| 30 | 6.276 | 6.286 | -0.011 |
| 31 | 5.983 | 5.867 | 0.1161 |
| 32 | 6.066 | 5.858 | 0.2075 |
| 33 | 6.337 | 6.202 | 0.1356 |
| 34 | 6.553 | 6.644 | -0.091 |
| 35 | 6.854 | 6.942 | -0.088 |
| 36 | 6.745 | 6.751 | -0.006 |
Test set.
Pearson's correlation, Variance Inflation Factor (VIF) and Mean Effect (MF) of descriptors used in the selected model.
| Descriptor | Inter-correlation | VIF | MF | |||||
|---|---|---|---|---|---|---|---|---|
| ATSC5i | GATS8p | minHBint3 | minHBint5 | MLFER_A | topoShape | |||
| ATSC5i | 1 | 1.391 | -0.005 | |||||
| GATS8p | -0.1181 | 1 | 2.994 | 0.983 | ||||
| minHBint3 | -0.3422 | 0.3350 | 1 | 1.500 | -0.010 | |||
| minHBint5 | -0.4024 | 0.6021 | 0.3330 | 1 | 5.148 | -0.020 | ||
| MLFER_A | 0.1375 | 0.1420 | 0.1317 | -0.5053 | 1 | 2.704 | -0.110 | |
| topoShape | -0.0275 | -0.0451 | 0.2254 | -0.2468 | 0.2461 | 1 | 1.221 | 0.166 |
Y-Randomization test result.
| Model | R | R2 | Q2 |
|---|---|---|---|
| Original | 0.9726 | 0.9459 | 0.8883 |
| Random 1 | 0.4172 | 0.1741 | -0.7131 |
| Random 2 | 0.4080 | 0.1665 | -0.6273 |
| Random 3 | 0.6915 | 0.4782 | 0.0379 |
| Random 4 | 0.4669 | 0.2180 | -0.4743 |
| Random 5 | 0.6025 | 0.3631 | -0.2769 |
| Random 6 | 0.3653 | 0.1335 | -0.6688 |
| Random 7 | 0.4835 | 0.2338 | -0.6283 |
| Random 8 | 0.5267 | 0.2774 | -0.4792 |
| Random 9 | 0.2620 | 0.0686 | -0.8088 |
| Random 10 | 0.6430 | 0.4135 | -0.3519 |
| Random Models Parameters | |||
| Average r: | 0.4867 | ||
| Average r2: | 0.2526 | ||
| Average Q2: | -0.4990 | ||
| cRp2: | 0.8189 | ||
Figure 2(a) Plot of predicted activities against experimental activities (b) Plot of Standardized residuals against experimental activities of the compounds.
Figure 3Plot of the standardized residuals against the leverages (Williams plot).
Figure 43D interaction between Ligand 22 and pfLDH.